The serine/threonine protein kinase 11 (STK11) tumor suppressor gene is mutated in approximately 30% of NSCLC cases, making it the third most common site of genetic alterations in lung cancer after TP53 and KRAS [68]. This evidence concerns the gene STK11 and lung carcinoma.